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Abstract
Background: The study aims at revealing the fate of nanoparticles administered intravenously and
intraperitoneally to adult female mice, some of which were pregnant. Gold nanoparticles were
chosen as a model because these particles have been found to be chemically inert and at the same
time are easily traced by autometallography (AMG) at both ultrastructural and light microscopic
levels.
Results: Gold nanoparticles were injected intravenously (IV) or intraperitoneally (IP) and traced
after 1, 4 or 24 hours. For IV injections 2 and 40 nm particles were used; for IP injections 40 nm
particles only. The injected nanoparticles were found in macrophages only, and at moderate
exposure primarily in the Kupffer cells in the liver. IV injections resulted in a rapid accumulation/
clustering of nanoparticles in these liver macrophages, while the uptake in spleen macrophages was
moderate. IP injections were followed by a delayed uptake in the liver and included a moderate
uptake in macrophages located in mesenteric lymph nodes, spleen and small intestine.
Ultrastructurally, the AMG silver enhanced nanocrystals were found in lysosome-like organelles of
the Kupffer cells and other macrophages wherever located.
Accumulations of gold nanoparticles were not found in any other organs analysed, i.e. kidneys,
brain, lungs, adrenals, ovaries, placenta, and fetal liver, and the control animals were all void of AMG
staining.
Conclusion:  Our results suggest that: (1) inert gold nanoparticles do not penetrate cell
membranes by non-endocytotic mechanisms, but are rather taken up by endocytosis; (2) gold
nanoparticles, independent of size, are taken up primarily by Kupffer cells in the liver and
secondarily by macrophages in other places; (3) gold nanoparticles do not seem to penetrate the
placenta barrier; (4) the blood-brain barrier seems to protect the central nervous system from gold
nanoparticles; (5) 2 nanometer gold particles seem to be removed not only by endocytosis by
macrophages, and we hypothesize that part of these tiny nanoparticles are released into the urine
as a result of simple filtration in the renal glomeruli.
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Background
Nanotechnology is a rapidly developing field, and new
nanomaterials are daily introduced in new products
within electronics, foods, food containers, pharmaceuti-
cal drugs, cosmetics, paints and surface coatings [1]. This
trend will lead to an ever-increasing presence of nanopar-
ticles in the environment. Therefore, serious considera-
tions have to be made as to whether such particles are
harmful to life in general and man in particular. Concern-
ing nanoparticles with high stability one might worry
about the consequences of introducing matters with such
an immense surface area. Some metals that are otherwise
harmless, e.g. metallic zinc, become flammable, if pulver-
ized into micro- and nanosize particles. It is also known
that even a moderate exposure to such particulate matters
can cause damage to the organism [2]. Another concern is
that nanoparticles might penetrate epithelia in the lungs,
gastrointestinal tract, and skin and thereby spread in the
whole body [1,3,4].
In the present study we evaluated the biodistribution of
colloidal gold nanoparticles. Gold nanoparticles are being
used for diagnostics, therapy, research etc. [5-8]. With the
histochemical technique autometallography (AMG), gold
nanoparticles can be traced in morphologically intact tis-
sue [5,9-11]. As a model for evaluation of whether nano-
particles penetrate membranes if introduced parenterally,
we injected mice IV and IP with gold nanoparticles, sized
2 and 40 nm, respectively, and looked for them in differ-
ent organs including brain, lungs, liver, spleen, kidneys,
adrenals, ovaries, and small intestine. A group of pregnant
animals was included in order to evaluate reveal whether
gold nanoparticles penetrate the placenta barrier.
Results
In all mice exposed to gold nanoparticles accumulations
of nanoparticles were traced in Kupffer cells, i.e. in the
macrophages of the liver (Fig. 1a). No accumulations in
other cells than macrophages were seen in any of the
organs examined in this study and sections from the con-
trol animals were all void of AMG staining (Fig. 1c).
The fastest and most intense uptake was observed in
Kupffer cells from animals exposed IV to 40 nm nanopar-
ticles. All the Kupffer cells were loaded. In the animals
injected IV with 2 nm nanoparticles, the load of AMG sil-
ver enhanced nanoparticles was much less intense, and
was seen only in a fraction of the Kupffer cells of the liver
and some macrophages of the spleen. Animals given 40
nm nanoparticles IP showed far less intense staining of
the Kupffer cells and the number of loaded macrophages
was profoundly reduced. In these animals a moderate
uptake in the macrophages of mesenterial lymph nodes
(Fig. 1e) and in the lymphatic tissue in the wall of the
small intestine and in the spleen (Fig. 1d) were seen as
well.
Independent of exposure, the gold nanoparticles were
found ultrastructurally to accumulate in lysosome-like
structures of the macrophages supporting the notion that
nanoparticles are taken up by endocytosis (Fig. 2). Careful
scanning of AMG silver enhanced sections from kidneys,
brain, lungs, adrenals and ovaries of both IP and IV
injected animals did not reveal accumulation of nanopar-
ticles in these organs.
Transplacental transport
Pregnant mice injected IV revealed particle accumulation
in the liver of the dams as described above (Fig. 1a). The
mice were injected nanoparticles at days 16–18 of preg-
nancy and killed 24 hours after the last exposure by tran-
scardial perfusion with glutaraldehyde. Sections from
placentas and fetuses were AMG silver enhanced in order
to trace a possible entrance of gold nanoparticles. No par-
ticles were found in the fetuses (Fig. 1b) or in the placen-
tas.
Discussion
Gold nanocrystals will be silver enhanced if exposed to an
autometallographic developer. The AMG technique is
based on the catalytic qualities of gold nanoparticles caus-
ing silver ions adhering to their surfaces to be reduced to
metallic silver atoms powered by electrons released from
reducing molecules [9,11]. Some few other metal contain-
ing nanocrystals have the same quality making it impera-
tive to include tissue from untreated animals in the
analysis. The only other pure metal nanoparticle known
to be AMG amplifiable is made of silver atoms. However,
mercury, bismuth and silver have been proved to be
metabolized into metal – sulphur respectively metal –
selenium nanoparticles when introduced in organisms.
These nanoparticles can also be enhanced by AMG [11].
The finding that gold nanoparticles can be traced by auto-
metallography was presented in 1981 [9] and three years
later the technique was implemented as a tool for tracing
RNA and antigens with gold tagged RNA-ase and antibod-
ies [5,11,12]. The amplification power of AMG is substan-
tial – e.g. a 14 nanometer gold nanoparticle will be silver
amplified 3,5 times if placed in a silver lactate developer
for 15 minutes. A single particle can be detected by AMG
even if it is just a fraction of a nanometer in diameter
[11,13]. Therefore all the 2 and 40 nanometer gold nano-
particles present in the analyzed tissue will be AMG silver
enhanced. Today, the technique is widely used for multi-
tude of purposes and AMG developers are commercially
available as are different molecules tagged with gold nan-
oparticles or AMG traceable quantum dots [11,14].Particle and Fibre Toxicology 2007, 4:10 http://www.particleandfibretoxicology.com/content/4/1/10
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Micrographs demonstrating AMG silver enhanced clustered gold nanoparticles in mouse after in vivo exposure Figure 1
Micrographs demonstrating AMG silver enhanced clustered gold nanoparticles in mouse after in vivo exposure. (a) 40 nm gold 
particles clustered in Kupffer cells of the liver from a pregnant mouse. (b) Section from a fetal liver taken from an embryo of 
the same animal. Note that the fetal tissue is completely void of staining. The pregnant animal was intravenously injected 40 nm 
gold particles and allowed to survive for 24 hours. Both sections were 3 micron Epon sections counterstained with toluidine 
blue. (c) Section from the liver of a pregnant mouse, which served as a control and was exposed to saline. The section is com-
pletely void of AMG staining; (d) Micrograph of nanogold particles in a spleen macrophage. The animal was treated intrave-
nously with 40 nm gold particles 24 hours before being sacrificed. 3 micron Epon section counterstained with Toluidine blue. 
(e) Enhanced gold nanoparticles in macrophages of a mesenterial lymph node. The animal was injected 40 nm gold nanoparti-
cles intraperitoneally and allowed to survive for 4 hours, 30 µm thick cryo section, counterstained with toluidine blue. (f) 
Micrograph of a mesenterial lymph node of a mouse which was exposed to saline intraperitoneally and served as control. Scale-
bars = 20 µm.Particle and Fibre Toxicology 2007, 4:10 http://www.particleandfibretoxicology.com/content/4/1/10
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In the present study, we used gold nanoparticles as a
model. Gold nanoparticles were considered suitable as a
model for studying cellular uptake of nanoparticles
because: 1) they are believed to be totally inert, i.e. have
no adverse effects [15]; 2) they can be silver enhanced by
AMG to visible sizes [5,9,11]. We decided to use 2 and 40
nm particles in order to test if any biodistribution patterns
could be related to particle size.
The finding that both 2 and 40 nm particles accumulate
overwhelmingly in the Kupffer cells of the liver is some-
what surprising. Even after IP injections, where a substan-
tial part of the particles must be expected to pass through
one or more lymph nodes packed with macrophages,
AMG silver enhanced gold particles were found only in
relatively few macrophages and only in few animals.
Pilot experiments in our laboratory have indicated that
macrophage cultures phagocytose gold nanoparticles eas-
ily, and we therefore would have expected to constantly
find gold nanoparticles in macrophages in lymph nodes
draining the injection site. At this point we think that as
the IP injected nanoparticles might have penetrated the
peritoneum any places in the abdomen we might only by
change have removed the "right" lymph node i.e. the ones
draining a region where substantial amounts of nanopar-
ticles have penetrated. However, our results prove beyond
doubt that the Kupffer cells are central in the elimination
process of nanoparticles that cross the epithelial barriers
of the body.
The reasons why exposure to 2 nm particles resulted in a
loading of only a minor part of the Kupffer cells even
when given IV could be: 1) The concentration of gold: 1 ml
of colloidal gold containing 40 nm particles contains
58.21 micrograms of pure gold, whereas 1 ml of colloidal
gold with 2 nm particles contains just 12.13 micrograms
of pure gold. 2) Glomerular filtration: Current knowledge
on glomerular filtration [16,17] allows us to suggest that
2 nm gold nanoparticles are filtrated via the kidneys,
Electron micrographs showing AMG enhanced clustered gold nanoparticles in the lysosomes of a Kupffer cell (a) and a spleen  macrophage (b) Figure 2
Electron micrographs showing AMG enhanced clustered gold nanoparticles in the lysosomes of a Kupffer cell (a) and a spleen 
macrophage (b). The animal was exposed to 40 nm gold nanoparticles intravenously and allowed to survive for 24 hours. Scale-
bars = 2 µm.Particle and Fibre Toxicology 2007, 4:10 http://www.particleandfibretoxicology.com/content/4/1/10
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while 40 nm nanoparticles definitely cannot be filtrated.
This is expected drastically to influence the amount of cir-
culating 2 nm particles. For humans the whole blood vol-
ume is filtered through the kidney within one hour, we
have not been able to find the figures on mice.
The clear difference in gold nanoparticle uptake by the
Kupffer cells, depending on the route of exposure, is most
likely a result of a delayed presentation of the particles to
the Kupffer cells after IP injections compared to IV injec-
tions. It is surprising, though, that the particles given IP
are not taken up primarily by the myriads of macrophages
which they must pass before reaching the liver.
We have not yet measured the time that the Kupffer cells
stay in the liver after they have been loaded with nanopar-
ticles. Such information will be important for our under-
standing of the nanoparticle trafficking in the mammalian
organism in the time-scale before elimination.
Following IV injection, the Kupffer cells were heavily
loaded after one hour, while only a fraction of the cells
were lightly loaded one hour after an IP injection.
Our findings confirm almost to the point the results of
Singer et al. [18] and Adlersberg and Singer [19]. These
scientists performed two studies using 300 mice in each
study. They exposed mice both IV and IP to both radioac-
tive 198Au and nonradioactive colloidal gold nanoparti-
cles with a diameter of 3–7 nm. Tissues were analyzed by
measuring radioactivity and by light microscopy. The
dose they used for histological observations was 250
micrograms, i.e. more than 4 times larger than the dose
we used. Already one hour after exposure approximately
90% of the nanoparticles were accumulated in the liver
while the remaining 10% accumulated in the rest of the
body. Histologically, they found gold nanoparticles to be
localized inside the macrophages. Accumulation of radio-
active colloidal gold particles was primarily found in the
liver and lymph nodes in animals and man, in the other
studies using IP administration [20-22].
The finding that there was no significant difference in
accumulation patterns within the three survival periods
applied in our study (1, 4 and 24 hours) suggests that
once gold nanoparticles have entered the blood circula-
tion, they will either be trapped by the Kupffer cells in the
liver, or if smaller than about 4–6 nm partially be filtrated
into the preurine. A study performed by Heinfeld et al. [8]
with 1.9 nm Au particles, supports this suggestion. In their
study gold nanoparticle retention in the liver and spleen
was low suggesting elimination through the kidneys. This
mechanism seems to be very efficient and capable of pro-
tecting the rest of the organism from the nanoparticles.
Any cells able to pick up nanoparticles by endocytosis, i.e.
pinocytosis or phagocytosis, will either take them up in
lysosomes/phagocytomes, or export them out of the cell
again. Pinocytosis might e.g. be an important factor in the
transport of nanoparticles across the blood vessel wall.
Recent studies have suggested that transcytosis system
across the endothelium is caveollae-mediated process
[23]. Considering that caveolae are 50 – 80 nm in size
[24], 2 and 40 nm gold particles most likely pass cell bar-
riers by transcytosis.
Transplacental transport
Gold nanoparticles have been administered to pregnant
animals before. Challier et al. [25] used 4–200 nm gold
radiocolloid particles and demonstrated impermeability
of rat placenta in both directions, i.e., mother-fetus and
fetus-mother. Our findings support this. However, Taka-
hashi and Matsuoka [26] exposed rats IV to 5 and 30 nm
198Au particles and reported an insignificant transfer to
the fetus, i.e. 0.018 and 0.005% for 5 and 30 nm particles,
respectively. In our study, there were no traces of gold
nanoparticles neither in fetus nor placenta, which suggests
that those particles cannot cross the placenta barrier.
Conclusion
Our results suggest that: (1) gold nanoparticles do not
penetrate cell membranes by non-endocycytotic mecha-
nisms, but is rather transported through cells by transcy-
tosis (2) gold nanoparticles in the 2–40 nm interval are
taken up primarily by Kupffer cells in the liver and sec-
ondarily by macrophages in the spleen and in other
places; (3) gold nanoparticles do not seem to penetrate
the placenta barrier; (4) the blood-brain barrier seems to
protect the central nervous system from gold nanoparti-
cles; (5) endocytosis by macrophages seems not to be the
only way that the organism use to eliminate 2 nanometer
gold particles. We hypothesize that part of these tiny nan-
oparticles are released into the urine as a result of simple
filtration in the renal glomeruli.
Methods
Gold nanoparticles
We used 2 and 40 nm colloidal gold nanoparticles. The 2
nm gold nanoparticles solution contained 15 × 1013 parti-
cles per 1 ml (12.13 micrograms) while the 40 nm gold
solution contained 9 × 1010 particles per 1 ml (58.21
micrograms) Both 2 nm and 40 nm gold nanoparticles
were acquired from Fitzgerald Industries Inc, USA. These
particles were made by citrate reduction and therefore had
a negative surface charge. The gold nanoparticles were
monodisperse and spherical in shape. The solution addi-
tionally contained 0.01% AuCl and traces of citrate, pH =
5.5.Particle and Fibre Toxicology 2007, 4:10 http://www.particleandfibretoxicology.com/content/4/1/10
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The animal model
The study was undertaken in accordance to the Danish
law and the University of Aarhus guidelines for animal
welfare. A total of 46 female C57BL/6 mice were used, 13
of which were pregnant. The 33 non-pregnant animals
were 120 days old at a body of weight of 18 to 21 grams.
They were divided into nine experimental groups and two
control groups, each consisting of 3 mice. Six experimen-
tal groups were injected IV with 1 ml colloidal gold con-
taining either 2 or 40 nm gold nanoparticles. The
intravenous injections were given into the tail vein. The
injections were performed slowly, over a period of no less
than 5 min per injection. The animals were carefully
observed during the injection procedure and the observa-
tion continued one hour after its termination. Three
experimental groups were exposed IP to 1 ml colloidal
gold, containing 40 nm gold nanoparticles. 6 mice served
as controls: 3 of them were exposed to 1 ml saline IV, and
the other 3 to 1 ml saline IP. To prevent any possible dis-
comfort for the animals during the post exposure period,
analgesia was ensured by adding buprenorphin to the
drinking water. The animals were housed in plastic cages
under the following conditions: 12 h light/dark cycle, 22
+/- 2°C and 50 +/-10% relative humidity. Food (Altromin
No. 1314, Altromin Spezialfutterwerke, Germany) and
tap water were available ad libitum. The nine experimen-
tal groups were allowed to survive for: 1, 4 and 24 hours,
respectively, and the control groups 24 hours.
The pregnant animals were in their 16–18th day of preg-
nancy, at a body weight of 29 – 31 grams. They were
divided into two experimental groups of five animals.
These groups received IV 1 ml of a solution containing 2
nm gold nanoparticles and 1 ml of a solution containing
40 nm gold nanoparticles, respectively. The remaining
three pregnant animals served as controls and were
exposed to 1 ml saline IV.
All mice were anesthetized with isofluran and sodium
pentobarbital (50 mg/kg body weight) and transcardially
perfused at 120 mm Hg with 3% buffered glutaraldehyde
for 5 min (1 min of rapid flow followed by 4 min of
reduced flow 5–10 ml/min). The brain, small intestine
(ileum), mesenterial lymph nodes, liver, spleen, kidneys,
adrenals, and ovaries were excised and placed in glutaral-
dehyde for 24 hours at 8°C temperature. From the preg-
nant mice fosters, placenta and liver from the mother
animals were excised.
Tissue processing
The organs selected for cryostat sectioning were placed in
30% sucrose until they sank to the bottom of the jar. They
were frozen with carbon dioxide and cut into 30 microm-
eters sections on a Dittes-Duspiva Cryostat, placed on
glass slides, dried and coated with gelatin.
Tissue to be embedded in Epon blocks was cut in approx-
imately 2 × 2 × 2 mm blocks with a razorblade or scalpel
and rinsed in 0.10 M phosphate buffer (pH 7.4) for 2 × 5
min, then dehydrated in graded ethanol solutions and
embedded in Epon. Semithin sections (3 µm) were cut
with an ultramicrotome (Leica EM UC6) and placed on
glass slides before being AMG developed. After light
microscopic analyses, selected sections were re-embedded
on top of a blank Epon block and trimmed to include
only the regions of interest. Thereafter, ultrathin sections
were cut and counterstained with lead citrate and uranyl
acetate before electron microscopic analysis (Philips Mor-
gagni 268D).
AMG development
The AMG developer consisted of a 60 ml gum arabic solu-
tion and 10 ml sodium citrate buffer (25.5 g of citric acid
· 1H2O + 23.5 g sodium citrate · 2H20 to 100 ml distilled
water). Immediately before use 15 ml reductor (0.85 g of
hydroquinone dissolved in 15 ml distilled water at 40°C)
and 15 ml of a solution containing silver ions (0.12 g sil-
ver lactate in 15 ml distilled water at 40°C) were added,
and the AMG developer was thoroughly stirred [11]. The
glass slides were put in a jar filled with the AMG developer
and placed in a water bath at 26°C. The entire set-up was
covered with a dark hood. During the AMG development
an electric device shook the jars gently. After 60 minutes
the AMG development was stopped by rinsing the slices in
water and afterwards replacing the developer with a 5%
sodium thiosulphate solution for 10 min (the AMG stop
bath solution). The jars were then placed under gently
running water for 20 minutes.
Post AMG treatment
The sections from the different sources were counter-
stained with a 0.1% aqueous toluidine blue solution (pH
4.0), dehydrated in alcohol to xylene, and ultimately
embedded in DEPEX and covered with a cover glass. Black
silver grains represented silver-encapsulated gold nano-
particles. All procedures and protocols have previously
been described in details [11].
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